Prostate Cancer Clinical Trials in Kansas City, Kansas

7 studies are recruiting for prostate cancer in Kansas City, Kansas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

   This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity of [225Ac]Ac-AKY-2519 in participants with metastatic castration-resistant pro…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Locations

   6 in total

   Run by

   Aktis Oncology, Inc.

   See if you can join NCT07581184 on ClinicalTrials.gov

2. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

   The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of stand…

   Stage

   Phase 3

   Ages

   18 to 100

   Site

   University of Kansas Hospital, Kansas City, Kansas

   Locations

   95 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06855277 on ClinicalTrials.gov

3. Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

   This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study i…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Kansas University Cancer Center, Kansas City, Kansas

   Locations

   14 in total

   Run by

   Monte Rosa Therapeutics, Inc

   See if you can join NCT07745361 on ClinicalTrials.gov

4. PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

   1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radiation therapy for prostate cancer, as compared to standard th…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Locations

   6 in total

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06274047 on ClinicalTrials.gov

5. HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer

   To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS) and/or urinary retention alters the treatment course for patients concurrently diagnosed with prostate cancer.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Kansas Health System, Kansas City, Kansas

   Run by

   University of Kansas Medical Center

   See if you can join NCT03802851 on ClinicalTrials.gov

6. TERPS Trial for de Novo Oligometastic Prostate Cancer

   This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   KU Medical Center- Cancer Center, Kansas City, Kansas

   Locations

   10 in total

   Run by

   University of Maryland, Baltimore

   See if you can join NCT05223803 on ClinicalTrials.gov

7. Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

   This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy. Treatment of interest: the investigational tre…

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   University of Kansas Hospital, Kansas City, Kansas

   Locations

   81 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06780670 on ClinicalTrials.gov